| Author | Perazzo, Hugo | |
| Author | Nunes, Estevão Portela | |
| Author | Cardoso, Sandra W. | |
| Author | Veloso, Valdilea G. | |
| Author | Grinsztejn, Beatriz | |
| Access date | 2024-11-27T15:00:51Z | |
| Available date | 2024-11-27T15:00:51Z | |
| Document date | 2024 | |
| Citation | PERAZZO, Hugo et al. Alignment of countries in the Americas with the latest WHO guidelines for hepatitis B virus (HBV) infection: a review. Lancet Regional Health. Americas, v. 39, p. 1-13, Oct. 2024. | en_US |
| ISSN | 2667-193X | |
| URI | https://www.arca.fiocruz.br/handle/icict/67309 | |
| Sponsorship | Hugo Perazzo has received support for the present study: (i) funding for the project “Randomized open-label and non-inferiority clinical trial to evaluate treatment retention, safety and cost-effectiveness of simplified and decentralized HCV treatment compared to standard-of-care in the Brazilian Public Health System” from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) grant number 445957/2020–4 and (ii) funding as Young Investigator from Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ) grant number E-26/201.351/2021. Estevão Portela Nunes, Sandra Wagner Cardoso, Valdilea Gonçalves Veloso and Beatriz Grinsztejn have nothing to disclosure. | |
| Language | eng | en_US |
| Publisher | Elsevier | |
| Rights | open access | en_US |
| Title | Alignment of countries in the Americas with the latest WHO guidelines for hepatitis B virus (HBV) infection: a review | en_US |
| Type | Article | |
| DOI | 10.1016/j.lana.2024.100925 | |
| Abstract | Evidence is lacking on alignment of current guidance from the Region of the Americas (AMR) countries with the new guidelines for people with hepatitis B virus (HBV) infection published by the World Health Organization (WHO) in March 2024. We gathered the most updated guidance on HBV infection from organisations/societies and seven countries from AMR. Most guidelines were aligned with the new WHO recommendation to treat persons with elevated ALT and HBV-DNA levels ≥2,000 IU/ml or with HIV-coinfection, hepatocellular carcinoma family history, extra-hepatic manifestations, or immunosuppression. The new WHO 2024 guidelines introduced treatment for persistently abnormal ALT in the absence of HBV-DNA, with TDF and/or entecavir as first-line therapy. TDF in pregnant women with high HBV-DNA levels was recommended to prevent mother-to-child transmission (MTCT). These guidelines advised prophylaxis to pregnant women with positive HBsAg where HBV-DNA is unavailable. WHO 2024 and updated guidelines from most AMR countries had simplified and expanded criteria for HBV treatment and MTCT prevention. | en_US |
| Affilliation | Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil. | en_US |
| Affilliation | Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil. | |
| Affilliation | Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil. | |
| Affilliation | Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil. | |
| Affilliation | Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil. | |
| Subject | Hepatitis B | |
| Subject | Treatment | |
| Subject | Mother to child transmission | |
| Subject | Non-invasive tests | |
| Subject | Guidelines | |
| e-ISSN | 2667-193X | |
